Search

Pipeline

Driven by data and science, we apply our innovative TransCon technology platform to develop therapies that aim to address unmet medical needs. Below is an overview of our rare endocrine disease clinical development pipeline.

Endocrine Rare Diseases

Ascendis Programs
Clinical Trial
Phase
Location
Lonapegsomatropin-tcgd (TransCon hGH)
Turner Syndrome
New InsiGHTS
NCT05690386
Phase 2
United States
Growth Hormone Sufficient Conditions
HighLiGHts
NCT07221851
Phase 3
Multinational
Palopegteriparatide (TransCon PTH)
Hypoparathyroidism
PaTHway60
NCT07081997
Phase 3
United States
Navepegritide (TransCon CNP)
Achondroplasia (Children ages 2-11)
ApproaCH
NCT05598320
Pivotal
Multinational
Achondroplasia
AttaCH
NCT05929807
Phase 2
Multinational
Achondroplasia (Children ages 0-2)
reACHin
NCT06079398
Phase 2
Multinational
Achondroplasia (Adolescents ages 12-18)
teACH
NCT06732895
Phase 2
Multinational
Navepegritide + Lonapegsomatropin-tcgd
Achondroplasia (Children ages 2-11)
COACH
NCT06433557
Phase 2
Multinational

TransCon product candidates are also in development in other indications and countries through strategic partnerships.

This section includes pipeline drug candidates currently undergoing clinical testing that may not be FDA-approved and therefore safety and efficacy have not been established.  There is no guarantee that pipeline products or investigational uses will obtain FDA approval. This information is current as of 03/26.